Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Colorectal cancer.

Shibani Nicum1, Rachel Midgley, David J Kerr

  • 1Department of Clinical Pharmacology, The University of Oxford, Radcliffe Infirmary, Oxford, UK. shibani.nicum@clinical-pharmacology.oxford.ac.uk

Acta Oncologica (Stockholm, Sweden)
|August 6, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reliable classification of polyps based on artificial intelligence: a development and validation study.

EClinicalMedicine·2026
Same author

Risk of Cancer With Hormone Replacement Therapy: A Narrative Review.

BJOG : an international journal of obstetrics and gynaecology·2026
Same author

Generalisation of automatic tumour segmentation in histopathological whole-slide images across multiple cancer types.

NPJ precision oncology·2026
Same author

Targeting TFAP2β condensation suppresses the development of esophageal squamous cell carcinoma.

Cell·2025
Same author

Early-stage lung adenocarcinoma affects DNA methylation and gene expression in adjacent tissues.

EMBO reports·2025
Same author

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2025
Same journal

Overall survival following palliative immune checkpoint inhibitor treatment according to ECOG performance status: a large registry-based study.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

Pathological characteristics and prognosis of very young patients with early breast cancer: a comparative analysis with older patients.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

Recent survival trends in the most fatal cancers in the Nordic countries: gains in some but not in all.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

First-in-human quantitative [¹⁵O]H₂O PET imaging of tumour blood flow at rest and during exercise in lymphoma patients.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

Starshot field configuration in the linac isocentre size determination: a comparison of film and electronic portal imaging device measurements.

Acta oncologica (Stockholm, Sweden)·2026
Same journal

Perspectives on artificial intelligence-generated chronic disease risk predictions in early breast cancer: an international survey among radiation oncologists.

Acta oncologica (Stockholm, Sweden)·2026
See all related articles

Colorectal cancer (CRC) treatment advances include chemotherapy and radiotherapy. Novel molecular strategies and targeted agents show promise for improved cure rates and survival in CRC patients.

Area of Science:

  • Oncology
  • Gastroenterology

Background:

  • Colorectal cancer (CRC) is a major cause of mortality globally.
  • Current treatments like chemotherapy and radiotherapy improve outcomes for advanced CRC.

Purpose of the Study:

  • To review CRC pathogenesis.
  • To present evidence for current and novel CRC treatment strategies.

Main Methods:

  • Literature review of CRC pathogenesis.
  • Review of clinical evidence for chemotherapy and novel agents.
  • Overview of ongoing phase I and II trials.

Main Results:

  • Advances in understanding CRC molecular basis offer new therapeutic avenues.
  • Novel targeted agents demonstrate efficacy in CRC treatment.

Related Experiment Videos

  • Improved treatment strategies aim to increase cure rates and survival.

    • Conclusions:

    • Understanding CRC molecular progression is key to developing novel therapies.
    • Chemotherapy, radiotherapy, and targeted agents are crucial for CRC management.
    • Ongoing trials are evaluating promising new CRC treatment strategies.